Beijing Yuan Xin Funding, Investors & Competitors

Beijing Yuan Xin has raised $850M across 4 funding rounds, most recently a $232M Series F in August 2021.

Last Beijing Yuan Xin funding round

$232M

Series F · Aug 2021

Cumulative funding Beijing Yuan Xin raised

$850M

across 4 funding rounds

Key investors in Beijing Yuan Xin

Beijing Yuan Xin Overview

About Beijing Yuan Xin

Beijing Yuan Xin is a Beijing-based technology company operating an integrated healthcare platform for pharmaceutical distribution and health insurance services. It connects suppliers, pharmacies, and insurers to streamline drug supply chains and reimbursement processes across China.


Founded

2015

HQ

ChinaBeijing

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Beijing Yuan Xin Funding History

Beijing Yuan Xin has raised a total of $850M across 4 funding rounds.

Beijing Yuan Xin's first fundraising round was a $73M Series C in January 2019. The most recent completed round was a $232M Series F in August 2021.

Beijing Yuan Xin funding rounds

Beijing Yuan Xin funding rounds
DateStageInvestorsRaised
Aug 2021Series FHel Ved Capital; Kun Ling Capital; Index Capital; Future Innovation Fund; Sequoia Capital; BOCI Asia; Archerman Capital; OrbiMed; B Capital; eFund; CITIC Securities; INCE Capital$232M
Feb 2021Series EHSG (lead); Tencent (lead); Qiming Venture Partners; CICC Capital; CITIC Securities$465M
Jun 2020Series DIndex Capital; Qiming Venture Partners; CITIC Securities; HSG; INCE Capital$80M
Jan 2019Series CTencent (lead); HSG$73M

Who has invested in Beijing Yuan Xin?

16 investors have backed Beijing Yuan Xin across its funding rounds, including HSG, CITIC Securities, Qiming Venture Partners, Tencent, INCE Capital and Index Capital.

Lead investors include HSG and Tencent.


Beijing Yuan Xin Investors

Investors in Beijing Yuan Xin by funding rounds participated
InvestorHQRoundsRoleFirst check
CITIC SecuritiesChinaShenzhen3ParticipantJun 2020
HSGHong KongHong Kong3LeadJan 2019
Index CapitalChinaBeijing2ParticipantJun 2020
TencentChinaShenzhen2LeadJan 2019
Qiming Venture PartnersChinaShanghai2ParticipantJun 2020
INCE CapitalChinaShanghai2ParticipantJun 2020
Hel Ved CapitalHong KongHong Kong1ParticipantAug 2021
Kun Ling CapitalChinaShanghai1ParticipantAug 2021
Future Innovation FundUAEUAE1ParticipantAug 2021
CICC CapitalChinaBeijing1ParticipantFeb 2021
Sequoia CapitalUnited StatesSan Francisco, CA1ParticipantAug 2021
BOCI AsiaHong KongHong Kong1ParticipantAug 2021
Archerman CapitalUnited StatesBoston, MA1ParticipantAug 2021

This data is available for Pro users. Sign up to see all 16 Beijing Yuan Xin investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Beijing Yuan Xin Competitors

Beijing Yuan Xin competitors include listed companies like IQVIA, IDEXX Laboratories, GE HealthCare and ICON plc, and private ones like Benchling and Commure.

Public and private companies comparable to Beijing Yuan Xin
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
IDEXX LaboratoriesUnited StatesUnited StatesPublicly listed$4.3B$1.5B$40B8.9x
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
ICON plcUnited StatesUnited StatesPublicly listed$8.3B$816M$13B1.9x
BenchlingUnited StatesSan Francisco, CAPrivate$210M-$6.1B29.0x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x

Beijing Yuan Xin Public Comps

Beijing Yuan Xin is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, Amgen, Novo Nordisk and Gilead Sciences.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x
Amgen$37B$17B6.8x6.5x14.8x14.4x

This data is available for Pro users. Sign up to see all Beijing Yuan Xin competitors and their valuation data.

Start Free Trial

Common questions about Beijing Yuan Xin

When was Beijing Yuan Xin founded?Beijing Yuan Xin was founded in 2015.
Where is Beijing Yuan Xin headquartered?Beijing Yuan Xin is headquartered in Beijing, China.
Is Beijing Yuan Xin publicly listed?No, Beijing Yuan Xin is a private, VC-backed company.
How much funding has Beijing Yuan Xin raised?Beijing Yuan Xin has raised $850M across 4 funding rounds.
What was Beijing Yuan Xin's last funding round?Beijing Yuan Xin's last funding round was a $232M Series F in August 2021.
Who are Beijing Yuan Xin's investors?Beijing Yuan Xin's investors include CITIC Securities, HSG, Index Capital, Tencent, Qiming Venture Partners, INCE Capital, Hel Ved Capital, Kun Ling Capital, Future Innovation Fund, CICC Capital and 6 others.
Which companies are comparable to Beijing Yuan Xin?Companies comparable to Beijing Yuan Xin include IQVIA, IDEXX Laboratories, GE HealthCare, ICON plc, Benchling and Commure.

See companies similar to Beijing Yuan Xin

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial